Retrospective Study
Copyright ©The Author(s) 2016.
World J Hematol. Feb 6, 2016; 5(1): 37-50
Published online Feb 6, 2016. doi: 10.5315/wjh.v5.i1.37
Table 1 Hematological disease distribution and status of accessible and non-accessible examinations
DiagnosisNo. of patients
Examinations available in French Guiana
Myeloma27Complete blood count with cytology
Lymphoma (43 patients)Bone-marrow aspiration and biopsy
Burkitt1Common limited immunophenotypes
Follicular5Standard blood chemistry
CLL5LDH and β2-microglobulin
High-grade B-NHL9Standard immunological studies
MALT NHL4Immunoelectrophoresis (blood and urine)
T-NHL4Serological testing for HIV, HTLV1, HBV, HCV, EBV, as well as PCR/RT-PCR for these viruses, HHV8, HPV and the majority of infectious diseases (opportunistic or not)
Standard bone X-rays
CT scan
MRI
Examinations not available in French Guiana
ATL/lymphoma10PET scan
ATL/leukemia2Complete immunophenotypes
Hodgkin3Genetic testing
Myeloproliferative diseases (17 patients)
CML8
Thrombocytemia5
Acute leukemia4
Specific HIV-related entity (2 patients)
Kaposi2
Table 2 Characteristics, treatment and evolution of 22 patients with active multiple
No.GenderAgeIgStageRegimen 1Regimen 2Regimen 3FU (yr)
1M65IgAλIIIBBortezomib + DEXAMelphalan DEXA06
2F60IgGκNABortezomib + DEXA003
3M66IgAκNABortezomib + DEXA00< 1
4F77IgAκIIIBThalidomide + MelphalanMelphalan + DEXA0< 1
5F80NAIIIAThalidomide00< 1
6M56IgAκIIIBThalidomide + DEXAThalidomide + Melphalan02
7F71IgGκNABortezomib + DEXAThalidomide04
8F85IgGκIAMelphalan + DEXA006
9F62IgAλNAMelphalan + DEXABortezomib + DEXA07+
10M83NANANA00< 1
11F65IgGλIIIABortezomib + DEXA ThalidomideVAD011
12F81NAIIIBThalidomide + Melphalan + DEXA00< 1
13M57IgGκNABortezomib006
14F69IgGκIIIAMelphalan + Thalidomide,Lenalidomide04
15F59IgGκIIIABortezomib + DEXA + ThalidomideHDCT03+
16M44IgAκIIIBBortezomib + DEXAHDCT03
17F60IgGκIIIBDEXA+ Melphalan + ThalidomideHDCTLenalidomide6
18M52IgGλIIIABortezomib + DEXAHDCT02
19F61IgGκIIIBBortezomib + DEXA + ThalidomideHDCT02
20M62NANABortezomib + DEXAHDCTLenalidomide2
21M53IgAκIIIAVADHDCT012
22F55IgGκIIIABortezomib + DEXA + ThalidomideHDCT0< 1
Table 3 Characteristics, treatment and evolution of adult T-cell lymphoma-leukemia/lymphoma/leukemia
No.GenderAgeStageTumor sitesRegimen 1Regimen 2Regimen 3FU
ATL/lymphoma
1M28NAL/Z + P-IFN + oral ETOCHOP02
2M34IVL/Z + P-IFNCHOPDHAP3
3M38NAL/Z + P-IFNCHOPDHAP1
4F46IIIAbdomen, Ca2+CHOPVBl1
5M49IVCHOPDHAP< 1
6M49IVColon, CNSL/Z + P-IFNCHOPIT-MTX< 1
7F51IENasal, sinus0CHOP0< 1
8F58IIAL/Z + P-IFNCHOP03
9F62NAL/Z + P-IFN + ETO oralCHOP05
10M42IVCa2+R-CHOP003
ATL/leukemia
10M41-Liver, cavumL/Z + P-IFNCHOP0< 1
11F47-L/Z + P-IFN + oral ETOCHOP04
Table 4 Distribution of tumor types in patients infected by viruses
VirusHematological malignanciesSolid tumorsTotal
HIV91928
HTLV115419
HBV81018
HCV235
Total343670